Download PDF
CC BY 4.0 · TH Open 2023; 07(02): e128-e132
DOI: 10.1055/s-0043-1768946
Review Article

Quantitative Risk Evaluation of Adventitious Agents in Heparin

John Raedts
1   Aspen Oss B.V., Oss, The Netherlands
,
Edwin Kellenbach
1   Aspen Oss B.V., Oss, The Netherlands
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Heparin is typically extracted from domestic pigs, which may carry zoonotic adventitious agents. Prion and viral safety cannot be assured by testing the active pharmaceutical ingredient itself; instead for the evaluation of the adventitious agent (i.e., viruses/prions) safety of heparin and heparinoid (e.g., Orgaran or Sulodexide) therapeutics, a risk assessment is required. An approach is presented which provides a quantitative estimation of the worst-case potential residual adventitious agent (i.e., GC/mL or ID50) present in a maximum daily dose of heparin. This estimation is based on the input (determined by prevalence, titer, and amount of starting material to prepare a maximum daily dose) and validated reduction by the manufacturing process, resulting in an estimation of the worst-case potential level of adventitious agent present in a maximum daily dose. The merits of this quantitative, worst-case approach are evaluated. The approach described in this review provides a tool for a quantitative risk evaluation of the viral and prion safety of heparin.

Keywords

heparin - adventitious agents - viral safety - prion safety - virus reduction - prion reduction


Publication History

Received: 29 December 2022

Accepted: 17 April 2023

Article published online:
21 May 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 van der Meer JY, Kellenbach E, van den Bos LJ. From farm to pharma: an overview of industrial heparin manufacturing methods. Molecules 2017; 22 (06) 1025
    CrossrefPubMedGoogle Scholar
  • 2 McLEAN J. The discovery of heparin. Circulation 1959; 19 (01) 75-78
    CrossrefPubMedGoogle Scholar
  • 3 Plavsic M. An integrated approach to ensure the viral safety of biotherapeutics. Biopharm Int 2016; 29 (05) 40-45
    PubMedGoogle Scholar
  • 4 Roush DJ. Integrated viral clearance strategies-reflecting on the present, projecting to the future. Curr Opin Biotechnol 2018; 53: 137-143
    CrossrefPubMedGoogle Scholar
  • 5 European Commission. . Health and Consumers Directorate-General. June 26, 2018 Eudralex-EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, Manufacture of Biological active substances and Medicinal Products for Human Use, Vol. 4, Annex 2.
    PubMedGoogle Scholar
  • 6 World Health Organization. . Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks, Annex 3. WHO Technical Report Series, No. 978, 2013
    PubMed
  • 7 VanderWaal K, Deen J. Global trends in infectious diseases of swine. Proc Natl Acad Sci U S A 2018; 115 (45) 11495-11500
    CrossrefPubMedGoogle Scholar
  • 8 European Food Safety Authority (EFSA). . Accessed July 29, 2022 at: https://www.efsa.europa.eu/en
    PubMed
  • 9 The US Centers for Disease Control and Prevention (CDC). . Accessed July 29, 2022 at: https://www.cdc.gov/onehealth/basics/zoonotic-diseases.html
    PubMed
  • 10 World Organization for Animal Health (WOAH). . Accessed July 29, 2022 at: https://www.woah.org
    PubMed
  • 11 World Animal Health Information System. . Accessed July 29, 2022 at: https://wahis.woah.org/#/home
    PubMed
  • 12 The EU Animal Diseases Information System (ADIS). . Accessed July 29, 2022 at: https://ec.europa.eu/food/animals/animal-diseases/animal-disease-information-system-adis_en
    PubMed
  • 13 European Food Safety Authority (EFSA). . Accessed July 29, 2022 at: https://www.efsa.europa.eu/en/topics/topic/african-swine-fever
    PubMed
  • 14 Opriessnig T, Huang YW. Third update on possible animal sources for human COVID-19. Xenotransplantation 2021; 28 (01) e12671
    CrossrefPubMedGoogle Scholar
  • 15 Shi J, Wen Z, Zhong G. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 2020; 368 (6494): 1016-1020
    CrossrefPubMedGoogle Scholar
  • 16 Schlottau K, Rissmann M, Graaf A. et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe 2020; 1 (05) e218-e225
    CrossrefPubMedGoogle Scholar
  • 17 Bonilauri P, Rugna G. Animal coronaviruses and SARS-COV-2 in animals, what do we actually know?. Life (Basel) 2021; 11 (02) 123
    PubMedGoogle Scholar
  • 18 Maurin M, Fenollar F, Mediannikov O, Davoust B, Devaux C, Raoult D. Current status of putative animal sources of SARS-CoV-2 infection in humans: wildlife, domestic animals and pets. Microorganisms 2021; 9 (04) 868
    CrossrefPubMedGoogle Scholar
  • 19 Gerhards NM, Cornelissen JBWJ, van Keulen LJM. et al. Predictive value of precision-cut lung slices for the susceptibility of three animal species for SARS-CoV-2 and validation in a refined hamster model. Pathogens 2021; 10 (07) 824
    CrossrefPubMedGoogle Scholar
  • 20 Sikkema RS, Tobias T, Oreshkova N. et al. Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands. Emerg Microbes Infect 2022; 11 (01) 91-94
    CrossrefPubMedGoogle Scholar
  • 21 World Organization for Animal Health (WOAH). . Accessed July 29, 2022 at: https://www.woah.org/en/?s=&_search=ebola
    PubMed
  • 22 Jandik KA, Kruep D, Cartier M, Linhardt RJ. Accelerated stability studies of heparin. J Pharm Sci 1996; 85 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 23 Al-Hakim A. General considerations for diversifying heparin drug products by improving the current heparin manufacturing process and reintroducing bovine sourced heparin to the US market. Clin Appl Thromb Hemost 2021; 27: 10 760296211052293
    CrossrefPubMedGoogle Scholar
  • 24 Buckingham R. Martindale: The Complete Drug Reference. Pharmaceutical Press; 2020
    Google Scholar
  • 25 Linhardt RJ, Sibel Gunay NUR. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 (Suppl 3): 5-16
    PubMedGoogle Scholar
  • 26 Vreeburg JW, Baauw A. Method for Preparation of Heparin from Mucosa. . Patent No. WO2010/110654 A1,24 March 2009
    PubMedGoogle Scholar
  • 27 Liu W, Wei MT, Tong Y. et al. Seroprevalence and genetic characteristics of five subtypes of influenza A viruses in the Chinese pig population: a pooled data analysis. Vet J 2011; 187 (02) 200-206
    CrossrefPubMedGoogle Scholar
  • 28 Ramirez A, Wang C, Prickett JR. et al. Efficient surveillance of pig populations using oral fluids. Prev Vet Med 2012; 104 (3–4): 292-300
    CrossrefPubMedGoogle Scholar
  • 29 Drohan WN, Cervenakova L. Safety of blood products: are transmissible spongiform encephalopathies (prion diseases) a risk?. Thromb Haemost 1999; 82 (02) 486-493
    PubMedGoogle Scholar
  • 30 World Organization for Animal Health (WOAH). . Accessed July 29, 2022 at: https://www.woah.org/en/disease/bovine-spongiform-encephalopathy
    PubMed
  • 31 Keire D. Manufacturing heparin with equivalent chemical composition from different animal sources. Thromb Haemost 2019; 119 (05) 688
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Aquino RS, Pereira MS, Vairo BC. et al. Heparins from porcine and bovine intestinal mucosa: are they similar drugs?. Thromb Haemost 2010; 103 (05) 1005-1015
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 European Food Safety Authority (EFSA). . Accessed July 29, 2022 at: https://www.efsa.europa.eu/en/press/news/150805
    PubMed
  • 34 European Commission. . June 29, 2011. Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. EMEA/410/01 Rev. 3. Official Journal of the European Union, 5.3. 2011
  • 35 Ruppach H. Log10 reduction factors in viral clearance studies. Bioprocess J 2014; 12 (04) 24-30
    CrossrefPubMedGoogle Scholar
  • 36 Ajayi O, Johnson S, Faison T. et al. An updated analysis of viral clearance unit operations for biotechnology manufacturing. Curr Res Biotechnol 2022; 4: 190-202
    CrossrefPubMedGoogle Scholar
  • 37 World Health Organization. . Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products, Annex 4. WHO Technical Report, Series No. 924, 2004
    PubMed
  • 38 Schielke A, Filter M, Appel B, Johne R. Thermal stability of hepatitis E virus assessed by a molecular biological approach. Virol J 2011; 8: 487
    CrossrefPubMedGoogle Scholar
  • 39 Buckow R, Isbarn S, Knorr D, Heinz V, Lehmacher A. Predictive model for inactivation of feline calicivirus, a norovirus surrogate, by heat and high hydrostatic pressure. Appl Environ Microbiol 2008; 74 (04) 1030-1038
    CrossrefPubMedGoogle Scholar
  • 40 Gröner A, Broumis C, Fang R. et al. Effective inactivation of a wide range of viruses by pasteurization. Transfusion 2018; 58 (01) 41-51
    CrossrefPubMedGoogle Scholar
  • 41 Farcet MR, Kindermann J, Modrof J, Kreil TR. Inactivation of hepatitis A variants during heat treatment (pasteurization) of human serum albumin. Transfusion 2012; 52 (01) 181-187
    CrossrefPubMedGoogle Scholar
  • 42 Nims RW, Plavsic M. Polyomavirus inactivation—a review. Biologicals 2013; 41 (02) 63-70
    CrossrefPubMedGoogle Scholar
  • 43 Turner C, Williams S, Burton C. et al. Laboratory scale inactivation of pig viruses in pig slurry and design of a pilot plant for thermal inactivation. Water Sci Technol 1998; 38 (4–5): 79-86
    CrossrefPubMedGoogle Scholar
  • 44 Aranha H, Forbes S. Viral clearance strategies for biopharmaceutical safety. Part 2: filtration for viral clearance. Pharm Technol 2001; 25 (04) 22
    PubMedGoogle Scholar
  • 45 Cameron R, Smith K. Virus clearance methods applied in bioprocessing operations: An overview of selected inactivation and removal methods. Pharm Bioprocess 2014; 2 (01) 75-83
    CrossrefPubMedGoogle Scholar
  • 46 van Engelenburg FA, Terpstra FG, Schuitemaker H, Moorer WR. The virucidal spectrum of a high concentration alcohol mixture. J Hosp Infect 2002; 51 (02) 121-125
    CrossrefPubMedGoogle Scholar
  • 47 Harris RE, Coleman PH, Morahan PS. Stability of minute virus of mice to chemical and physical agents. Appl Microbiol 1974; 28 (03) 351-354
    CrossrefPubMedGoogle Scholar
  • 48 Block S. Disinfection, sterilization, and preservation. 5th ed. Lippincott Williams & Wilkins; 2001
    Google Scholar
  • 49 Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe TW, Laub R. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost 1998; 80 (04) 624-631
    PubMedGoogle Scholar
  • 50 Lin Q, Lim JYC, Xue K. et al. Sanitizing agents for virus inactivation and disinfection. VIEW 2020; 1 (02) e16
    CrossrefPubMedGoogle Scholar